Pooled antibiotic susceptibility testing that evaluates how antibiotics perform against the infection as a whole — including in polymicrobial cases. Results in 24–36 hours.
ThinPrep cytology paired with the FDA-approved Aptima® HPV assay for high-risk HPV detection — with optional Aptima Combo 2® for chlamydia and gonorrhea.
The Pap smear is a screening procedure that aids in the detection of cancer and its precursors — not the sole means of detecting cervical cancer. Pairing it with molecular HPV testing strengthens the screening signal.
Indicated for cervical cancer screening for women between the ages of 24 and 65, in line with current screening guidelines.
Routine screening — cytology plus molecular HPV strengthens the signal.
A single ThinPrep specimen supports cytology, the Aptima® HPV assay, and the Aptima Combo 2® assay — one collection, multiple molecular reads.
Same vial for cytology and the molecular panels — no second draw.
The Aptima® HPV assay detects E6/E7 viral mRNA from high-risk HPV types 16, 18, 31, 33, 35, 39, 45, 58, 59, and 68.
FDA-approved in vitro nucleic-acid amplification — the high-risk types most relevant to cervical cancer.
The cytology read includes specimen source, specimen adequacy, descriptive findings, and additional findings — with recommended follow-up steps documented for the clinician.
An FDA-approved in vitro nucleic-acid amplification test detecting several high-risk HPV types. Positive results indicate qualitative detection of E6/E7 viral messenger RNA (mRNA) of any one or more high-risk HPV types in the cervical specimen. Negative results indicate HPV E6/E7 mRNA was not detected.
High-risk HPV types detected: 16, 18, 31, 33, 35, 39, 45, 58, 59, and 68.
An FDA-approved assay that detects the presence of Chlamydia trachomatis and Neisseria gonorrhoeae. Positive results diagnose chlamydia and/or gonococcal urogenital disease.
Indicated for cervical cancer screening for women between the ages of 24 and 65. Note: the Pap smear is a screening procedure, not the sole means of detecting cervical cancer — results should be interpreted alongside clinical context.
A single ThinPrep cervical specimen supports cytology, the Aptima® HPV assay, and the Aptima Combo 2® assay — one vial, multiple reads.
HPV types 16, 18, 31, 33, 35, 39, 45, 58, 59, and 68. Detection is based on E6/E7 viral mRNA via the FDA-approved Aptima® HPV assay.
Both are women's-health cytology tests. Cytology / High Risk HPV is a broader screening panel that pairs ThinPrep cytology with the Aptima® HPV and Aptima Combo 2® assays. GYN Cytology HR focuses on stratifying borderline Pap results — a different question, with a different marker panel.
Connect with a representative to learn how the panel fits into your cervical screening workflow.